Connect with us

Hi, what are you looking for?

DOGE0.070.84%SOL19.370.72%USDC1.000.01%BNB287.900.44%AVAX15.990.06%XLM0.080.37%
USDT1.000%XRP0.392.6%BCH121.000.75%DOT5.710.16%ADA0.320.37%LTC85.290.38%
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Entrepreneurship

Entrepreneurship

Novo to launch Wegovy in Asia with February roll-out in Japan

Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration/File Photo
Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration i... Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration/File Photo
Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration/File Photo
Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration i... Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration/File Photo

Listen to the article now

Novo Nordisk (NOVOb.CO) said on Thursday that it would introduce its top-rated anti-obesity medicine, Wegovy, in Japan on February 22. This will be the company’s first launch in Asia, even though it is already struggling to meet demand in its present regions.

Even though obesity is far less prevalent in Japan than in Western countries, Danish business has decided to debut Wegovy in Japan as the sixth nation in the world.

According to Novo, which is attempting to convince certain governments to pay for Wegovy for the most overweight people, most patients in Japan will pay 30% of their medical expenditures for Wegovy. This is in line with reimbursement for other pharmaceuticals.

According to Novo, a 0.25-milligram beginning dosage will cost 7,504 Japanese yen ($50.15) per month for patients, while a 2.4-milligram dose would be 42,960 Japanese yen each month.

According to Novo, patients in Japan will be eligible for the medicine if they have a body mass index (BMI) greater than 35 or a BMI greater than 27 and have two or more obesity-related co-morbidities.

The percentage of the population that is overweight or obese is relatively low in Japan. According to the data provided by the Global Obesity Observatory, just 4.5% of adults in Japan were obese in 2019. Obesity is defined as having a Body Mass Index (BMI) of 30 or more.

Wataru Ogawa, a professor at Kobe University, said that he was “very positive” about the arrival of Wegovy in Japan since lowering the symptoms of being overweight can have advantages for a wide variety of medical illnesses. These conditions include some forms of cancer and menstrual abnormalities.

Even though there are fewer cases of severe obesity in Japan compared to many Western nations, detrimental health impacts tend to show in East Asian populations at lower degrees of obesity, he added. This is the case even if Japan has fewer cases of extreme obesity than many Western nations.

“Japanese people are fragile to a small increase in body weight as compared to Caucasians,” said Ogawa, who works as an executive director of the Japan Society for the Study of Obesity. “Japanese people are fragile to a small increase in body weight as compared to Caucasians.”

Novo has had trouble keeping up with the skyrocketing demand for the medicine that suppresses appetite. As a result, the company has been forced to restrict the number of countries where it has released the therapy and the number of patients who may begin treatment.

To this point, the firm has only introduced Wegovy to the markets of its home country of Denmark, the United States of America, Great Britain, Germany, and Norway.

Wegovy is the first medicine of its kind to be commercially available, and it belongs to an innovative and highly successful new family of diet pills. However, industry observers believe that Novo’s inability to meet demand might give Eli Lilly (LLY.N), Novo’s competitor, a competitive advantage when introducing its Mounjaro weight-loss medicine.


Comment Template

You May Also Like

Business

India’s Economy Surpasses Predictions, Records Impressive 8.4% India has once again secured its position as the fastest-growing major economy globally, reporting an impressive expansion...

Economy

Gaza Post-War Plan Disclosed by Israel’s PM Netanyahu Israeli Prime Minister Benjamin Netanyahu has outlined his vision for post-war Gaza, proposing that Israel would...

Economy

Israel’s Economy Contracts More Than Anticipated Official figures reveal that Israel’s economy contracted more than anticipated in the aftermath of the conflict with Hamas...

Business

Small Business Marketing With Limited Time and Resources Thriving Against the Odds: The Ultimate Guide to Small Business Marketing on a Tight Schedule and...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok